01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
What can we really say about 2020?—a year more unique than any year we can remember. For financial ...
Read More >
On September 25, 2019, we reminded clients that the Diversity Visa Lottery would be open from Octobe...
Read More >
Hear how Hutchison PLLC provides strategic guidance to life sciences entrepreneurs to help them navi...
Read More >
On September 17, the US Department of the Treasury issued comprehensive proposed regulations to impl...
Read More >
The court of appeal held that an urgency ordinance enacted to impose a temporary moratorium on the e...
Read More >
Although the cases have slowed in some areas, we still expect a heavy flu season. According to the C...
Read More >